DeepMed Research

UNIVERSITY COLLEGE LONDON

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Established: 1826-02-11

Employees: 10K

Market Cap: -

Website: http://www.ucl.ac.uk

Clinical Trials

D-mannose for the Prevention of UTIs in Multiple Sclerosis

Phase 1

Conditions: Recurrent Urinary Tract Infections
Multiple Sclerosis

Interventions: Dietary Supplement: D Mannose

First Posted Date: 2015-07-03

Last Posted Date: 2015-07-03

Lead Sponsor: University College, London

Target Recruit Count: 20

Registration Number: NCT02490046

Locations: 🇬🇧
The National Hospital for Neurology and Neurosurgery, London, United Kingdom

Atherosclerosis in Familial Hypercholesterolemia

Conditions: Familial Hypercholesterolemia

Interventions: Other: CT coronary angiogram and carotid ultrasound

First Posted Date: 2015-07-02

Last Posted Date: 2015-07-02

Lead Sponsor: University College, London

Target Recruit Count: 100

Registration Number: NCT02489253

Locations: 🇬🇧
Royal Free Hospital, London, United Kingdom

Effect of Remote Ischaemic Conditioning in Oncology Patients

Not Applicable

Conditions: Cardiotoxicity

Interventions: Other: Placebo
Procedure: Remote Ischaemic Conditioning

First Posted Date: 2015-06-15

Last Posted Date: 2020-04-15

Lead Sponsor: University College, London

Target Recruit Count: 128

Registration Number: NCT02471885

Locations: 🇬🇧
University College London Hospitals, London, United Kingdom

Developing a Stepped Approach to Improving Sexual Function aFteR Treatment fOr gyNaecological Cancer

Not Applicable

Conditions: Uterine Cancer
Psychosexual Dysfunctions
Ovarian Cancer
Vaginal Cancer
Vulval Cancer
Cervical Cancer

Interventions: Behavioral: SAFFRON stepped care

First Posted Date: 2015-05-29

Last Posted Date: 2015-05-29

Lead Sponsor: University College, London

Target Recruit Count: 100

Registration Number: NCT02458001

CARPALL: Immunotherapy with CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia

Phase 1

Recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Procedure: Leukapheresis
Radiation: Total Body Irradiation (TBI)
Drug: Lymphodepletion with Fludarabine
Drug: Lymphodepletion with Cyclophosphamide
Biological: CD19+CD22 CAR T-cells

First Posted Date: 2015-05-14

Last Posted Date: 2025-04-02

Lead Sponsor: University College, London

Target Recruit Count: 50

Registration Number: NCT02443831

Locations: 🇬🇧
Great Ormond Street Hospital, London, United Kingdom
🇬🇧
University College Hospital, London, United Kingdom
🇬🇧
Manchester Royal Children's Hospital, Manchester, United Kingdom

Role of Cardiac Computed Tomography in Optimising Response to Cardiac Resynchronisation Therapy

Not Applicable

Conditions: Heart Failure

Interventions: Other: Heart scan

First Posted Date: 2015-05-05

Last Posted Date: 2015-05-05

Lead Sponsor: University College, London

Target Recruit Count: 100

Registration Number: NCT02434159

Locations: 🇬🇧
University College London Hospital, London, United Kingdom

Diet and Physical Activity in Uterine Cancer Survivors

Not Applicable

Completed

Conditions: Endometrial Neoplasms

Interventions: Behavioral: Shape-Up following cancer treatment

First Posted Date: 2015-05-04

Last Posted Date: 2020-05-19

Lead Sponsor: University College, London

Target Recruit Count: 60

Registration Number: NCT02433080

Locations: 🇬🇧
Barts Health NHS Trust, London, Greater London, United Kingdom
🇬🇧
University College London Hospital NHS Trust, London, Greater London, United Kingdom

Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation

Phase 1

Completed

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Leukapheresis
Drug: Cyclophosphamide
Drug: Fludarabine
Biological: CAR19 T-Cells

First Posted Date: 2015-05-01

Last Posted Date: 2023-04-28

Lead Sponsor: University College, London

Target Recruit Count: 10

Registration Number: NCT02431988

Locations: 🇬🇧
University College London Hospital, London, United Kingdom

Botulinum Toxin A Injections in Patients With Fowler's Syndrome

Phase 2

Completed

Conditions: Fowler's Syndrome
Urinary Retention

Interventions: Drug: onabotulinumtoxinA

First Posted Date: 2015-04-29

Last Posted Date: 2015-04-29

Lead Sponsor: University College, London

Target Recruit Count: 10

Registration Number: NCT02428881

Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination

Phase 1

Completed

Conditions: HIV

Interventions: Biological: pSG2.HIVconsv DNA vaccine
Biological: ChAdV63.HIVconsv booster vaccine
Biological: MVA.HIVconsv booster vaccine
Other: Placebo
Drug: CPHPC

First Posted Date: 2015-04-23

Last Posted Date: 2020-03-26

Lead Sponsor: University College, London

Target Recruit Count: 41

Registration Number: NCT02425241

Locations: 🇬🇧
National Amyloidosis Centre, London, England, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy